Australia’s competition watchdog has filed an appeal against a fine of $1.2 million imposed on British consumer goods giant Reckitt Benckiser for misleading consumers on painkiller marketing, arguing that it is too light.
Australia’s federal court this month imposed the penalty after finding Reckitt Benckiser had been deceptive in suggesting on its web site and packaging that its Nurofen Back Pain, Period Pain, Migraine Pain and Tension Headache products were formulated to target those types of pain although they all had the same active ingredient.
“The ACCC will submit to the Full Court of the Federal Court that A$1.7 million in penalties imposed on a company the size of Reckitt Benckiser does not act as an adequate deterrent and might be viewed as simply a cost of doing business,” Australian Competition and Consumer Commission Chairman Rod Sims said in a statement on Monday.
The commission has argued that a penalty of at least A$6 million would have been appropriate, in light of the millions of dollars in profits the company had made from the sale of those products.
Reckitt Benckiser, which has a market capitalization of $70 billion, said its Nurofen division was “carefully considering the appeal with its legal advisers.”
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK Probes Lindab’s Acquisition of HAS-Vent Amid Fears of Market Monopoly
Apr 28, 2024 by
CPI
Shein Faces EU Regulations Over User Data
Apr 28, 2024 by
CPI
Google Fights Back Against US Antitrust Lawsuit
Apr 28, 2024 by
CPI
US Homeland Security Establishes Blue-Ribbon Board with Tech CEOs to Advise on AI
Apr 28, 2024 by
CPI
FTC Accuses Amazon Executives of Using Disappearing Messaging Apps to Conceal Evidence
Apr 28, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI